Meeting
2017 Gastrointestinal Cancers Symposium
Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
Authors
Martin D. Berger
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Martin D. Berger , Sebastian Stintzing , Volker Heinemann , Dongyun Yang , Shu Cao , Yan Ning , Satoshi Okazaki , Yuji Miyamoto , Mitsukuni Suenaga , Marta Schirripa , Roel Gopez Jr., Diana L. Hanna , Wu Zhang , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 595)
DOI
10.1200/JCO.2017.35.4_suppl.595
Abstract #
595
Poster Bd #
D13
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.
First Author: Martin D. Berger
Poster
2018 ASCO Annual Meeting
Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.
First Author: Madiha Naseem
Poster
2016 ASCO Annual Meeting
Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort.
First Author: Yan Ning
Poster
2016 ASCO Annual Meeting
MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger